Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real-world study,Hepatology Research

当前位置： X-MOL 学术 › Hepatol. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real-world study
Hepatology Research ( IF 4.2 ) Pub Date : 2023-12-28 , DOI: 10.1111/hepr.14007
Jun‐Zhe Yi ₁ , Zhi‐Jian Zhu ₂ , Gong‐Wei Liu ₃ , Yi‐Min Zhang ₄ , Jie Xu ₁ , Xin‐Tong Wu ₄ , Ke Ding ₅ , Jian‐Chao Liu ₆ , Ke‐Fei Zhang ₇ , Xiong‐Ying Jiang ₁ , Qi‐Feng Chen _{1,

8,

9,

10} , Yue Hu ₁ , Song Chen ₁ , Sui‐Xing Zhong ₁ , Jiong‐Liang Wang ₁ , Ning Lyu _{1,

8,

9,

10} , Ming Zhao _{1,

8,

9,

10}

Affiliation

Department of Minimally Invasive Interventional Therapy Liver Cancer Study and Service Group Sun Yat‐sen University Cancer Center Guangzhou city China
Ganzhou Cancer Hospital Ganzhou city China
The Sixth Affiliated Hospital of Guangxi Medical University Yulin city China
Zhongshan School of Medicine Sun Yat‐sen University Guangzhou city China
Jiangmen Affiliated Hospital of Chinese Medicine Jinan University Jiangmen city China
Beihai People’s Hospital Guangxi Medical University Beihai city China
The Air Force Hospital of Southern Theater Command Guangzhou city China
State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China
Collaborative Innovation Center for Cancer Medicine Guangzhou China
Guangdong Provincial Clinical Research Center for Cancer Guangzhou China

The study was conducted to evaluate the feasibility and safety profile of hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (HAIC-FOLFOX) as an alternative therapeutic choice for patients with advanced hepatocellular carcinoma (HCC) that is refractory to systemic treatment including immune checkpoint blockades or molecular targeting agents.

中文翻译：